Format

Send to

Choose Destination
Am J Transplant. 2018 Dec 27. doi: 10.1111/ajt.15239. [Epub ahead of print]

Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-infected ESRD Patients: Pre vs. Post-Transplant.

Author information

1
University of Alabama at Birmingham Comprehensive Transplant Institute, Birmingham, AL, USA.
2
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
3
Boston University School of Medicine, Boston, MA, USA.

Abstract

End-stage renal disease (ESRD) patients co-infected with HCV and HIV have access to effective treatment options for HCV infection. However, they also have access to HCV-infected kidneys, which historically afford shorter times to transplantation. Given high waitlist mortality and rapid progression of liver fibrosis among co-infected kidney-only transplant candidates identifying the optimal treatment strategy is paramount. Two strategies, treatment pre- and post-transplant, were compared using Monte Carlo microsimulation of 1,000,000 candidates. The microsimulation was stratified by liver fibrosis stage at waitlist addition and wait-time over a lifetime time horizon. Treatment post-transplant was consistently cost-saving as compared to treatment pre-transplant due to the high cost of dialysis. Among patients with low fibrosis disease (F0-F1), treatment post-transplant also yielded higher life months (LM) and quality-adjusted life months (QALM) except among F1 candidates with wait-times >18 months. For candidates with advanced liver disease (F2-F4), treatment pre-transplant afforded more LM and QALM unless wait-time was < 18 months. Moreover, treatment pre-transplant was cost-effective for F2 candidates with wait-times > 71 months and F3 candidates with wait-times > 18 months. Thus, optimal timing of HCV treatment differs based on liver disease severity and wait-time, favoring pre-transplant treatment when cirrhosis development prior to transplant seems likely. This article is protected by copyright. All rights reserved.

PMID:
30589503
DOI:
10.1111/ajt.15239

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center